THE XBIOTM Solution
Next Science is leading a paradigm shift with a unique, unprecedented approach to eradicating both biofilm bacteria and planktonic bacteria with a proprietary, non-toxic technology that disrupts the biofilm’s extracellular polymeric substance (EPS) matrix and makes the bacteria within the biofilm more vulnerable to attack by antimicrobials, antibiotics and the body’s natural immune defences. This patented Xbio™ technology reduces the bacterial load and therefore may help to reduce the overall use of antibiotics, and it has shown no known evidence of bacterial resistance.59
MECHANISM OF ACTION
Next Science’s XbioTM uses proprietary composition-of-matter patents that contain technology to physically break down the biofilm’s protective structures, exposing and eradicating bacteria that are enveloped within the technology via cell lysis.
TARGET THE STRUCTURE
DECONSTRUCT THE BACTERIAL BIOFILM BARRIER
TARGET THE PATHOGENS
DESTROY BACTERIA WITHIN THROUGH CELL LYSIS
CONTROL THE ENVIRONMENT
Drawing on an extensive background in material science, Next Science is the leader in anti-biofilm solutions, with multiple in vitro and in vivo scientific and clinical studies, thorough safety testing, and effective technology delivery systems. Comprehensive and continuous research over time, applied to multiple applications, has resulted in the development of the most effective products currently available for the disruption of biofilm.
Unlike other agents that claim to destroy biofilms, there is no known resistance to the Next Science technology; variants are effective against any bacteria, persister cells or spores, and reduce the rate of biofilm recurrence over 100 times.60
Next Science has created a rapid-acting technology, providing options that have superior efficacy for both planktonic and biofilm bacterial forms. The Xbio™ technology is gentle, has low toxicity and has a favourable environmental impact. Learn more about pipeline opportunities and how Next Science is addressing the growing problem of biofilm-initiated antimicrobial resistance.